Skip to content
Likelier

Action vs. inaction: figure for each choice

When a mole changes or looks suspicious, do adults regret having it removed — or regret watching and waiting?

If you act

Having the suspicious mole removed

No direct measurement

If you don't

Watching and waiting

27%

At least one figure is an indirect estimate, not a measured regret rate. How each figure was built is shown below.


Health

Last reviewed 2026-06-21

Evidence quality 4.0/5

Eight-dimension review score against the quality rubric . Each dimension scored 1–5.

D1 Source verification
4/5
D2 Source authority & independence
5/5
D3 Regret-rate accuracy
3/5
D4 Source comparability
4/5
D5 Gilovich pattern
4/5
D6 Prose quality
4/5
D7 Caveat completeness
3/5
D8 Sample quality
5/5
Average 4.0/5
A dermatoscope resting beside a ruler and a magnifying loupe on a clinic desk
Indirect data: for this decision at least one figure comes from an indirect measure, such as outcomes, satisfaction or intent, or from an editorial estimate, rather than from a direct regret survey. The notes for each side below say how its figure was built.

If you act

Having the suspicious mole removed

No direct measurement

No source states a figure for this side, so none is shown.

Patients undergoing excision of melanocytic nevi

post-procedure, pooled across studies

If you don't

Watching and waiting

27%

27% of melanoma patients delayed presentation >3 months; 44% had not realised the change was serious (delayed-presentation proxy)

Melanoma patients, recalling pre-diagnosis delay

retrospective

Figure for each choice (the measure is named on the page)

Related decisions

Semantically similar decisions — same territory, different trade-offs.

Health

Remove asymptomatic wisdom teeth vs. monitor

Figure for each choice (the measure is named on the page)

Health

Risk-reducing mastectomy vs. surveillance

Figure for each choice (the measure is named on the page)

HealthDirect

Early diagnosis

% who regret this choice

Inaction dominates

Inaction regret 1.3× higher

Health

Tonsillectomy vs. watchful waiting

Figure for each choice (the measure is named on the page)

Health

LASIK eye surgery

Figure for each choice (the measure is named on the page)

Health

Alt-only vs. conventional cancer

Figure for each choice (the measure is named on the page)

Health

Quitting smoking

Figure for each choice (the measure is named on the page)

Health

Intervene in rehab vs wait

Figure for each choice (the measure is named on the page)

The decision only arises when a mole has changed or looks suspicious — leaving an ordinary stable mole alone is the right call for almost everyone, and removing every mole would be wholesale overtreatment. Once a mole is flagged, removing it is not free. A systematic review of 46 studies (4,201 lesions) found that surgical excision recurs in about 2% of cases and shave excision in roughly 11%, with cosmetic-satisfaction scores for surgical excision the lowest of any technique at 6.2 out of 10 — a real minority unhappy with the scar (Guo & Wang, 2026). And most suspicious moles turn out to be harmless: even consultant dermatologists excise about six benign lesions for every melanoma they find, a figure that climbs toward twenty in primary care (Sidhu et al., 2012). For most people who act, the excision will, in hindsight, have been unnecessary — the price paid for diagnostic certainty.

The watching-and-waiting side carries a regret of its own, one that is conditional but can be severe. Among people whose mole turned out to be melanoma, 27% had delayed presenting for more than three months, and 44% — the single most common barrier — had simply not realised the change was serious (O’Shea et al., 2017). A qualitative study found the mechanism plainly: changing moles are “often perceived as trivial,” patients delay to avoid “wasting the doctor’s time,” and three of four people later diagnosed with melanoma in that sample never sought help at all — their GP noticed the lesion opportunistically (Walter et al., 2010). The inaction harm is conditional: most who wait are fine, but for the minority whose mole is malignant, delay shifts the stage at diagnosis and can be fatal.

That conditionality is the whole story, and it is why these two numbers must not be read as a clean head-to-head. The action-side proxy is a cosmetic-and-recurrence rate across all excised nevi; the inaction-side proxy is a delay rate measured only among confirmed melanoma patients. They come from different populations, and the inaction figure overstates the risk for any single benign mole while understating the severity for the rare malignant one. How much regret either choice carries depends entirely on the base rate of malignancy in the specific lesion, which only a clinician can judge.

Sources: action

Claim ledger

Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.

2/2 sources independently verified verbatim against the cited source

  1. [1] Frontiers in Medicine (Guo & Wang 2026) — Aesthetic Techniques for Melanocytic Nevus Management: Clinical Outcomes, Cosmetic Satisfaction, and Safety — A Systematic Review and Meta-analysis Verified
    Aesthetic Techniques for Melanocytic Nevus Management: Clinical Outcomes, Cosmetic Satisfaction, and Safety — A Systematic Review and Meta-analysis
    Statistic
    Across 46 studies (4,201 lesions): surgical-excision recurrence 2.1%, shave-excision recurrence 10.7%; cosmetic-satisfaction scores 6.2/10 (surgical excision) to 8.8/10 (Er:YAG laser); adverse-event rates 11.2%–34.1%
    Excerpt
    “A total of 46 studies involving 4,201 lesions were included. Surgical excision demonstrated the highest clinical clearance rate (96.4%; 95% CI 92.1–99.2) and the lowest recurrence rate (2.1%). Laser-based treatments produced the most favorable cosmetic outcomes, with Er:YAG laser achieving the highest satisfaction score (8.8/10), followed by CO₂ laser (8.4/10), shave excision (7.6/10), and surgical excision (6.2/10). … Shave excision showed a higher recurrence rate of 10.7%, likely reflecting incomplete removal of deeper nevus cells. ”
    Source data from
    2026-01-01
    Accessed
    2026-11-16
    Verification
    Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
    Calculation
    Removing a mole rarely causes outright regret, but it is not free: surgical excision leaves a scar (the lowest cosmetic-satisfaction score, 6.2/10, reflecting a real dissatisfied minority), and shave excision recurs in ~10.7% of cases, sometimes prompting re-treatment. No action-side regret figure is shown: the recurrence and cosmetic-dissatisfaction signals describe a lingering negative outcome or re-treatment for a minority, not a regret survey.
  2. [2] Clinical and Experimental Dermatology (Sidhu et al. 2012) — The number of benign moles excised for each malignant melanoma: the number needed to treat Verified
    The number of benign moles excised for each malignant melanoma: the number needed to treat
    Statistic
    Mean number needed to treat (lesions excised per melanoma found, the melanoma included) was 6.3 among consultant dermatologists; 4,691 lesions over 2005–2009
    Excerpt
    “This was a retrospective analysis of data on pigmented lesions excised over a 5-year period (2005-2009). … The NNT ratio was calculated as (BN + DN + MM)/MM. … In total, 4691 lesions were examined. The overall mean NNT was 6.3, with a range of 4.9-11.3 for each of nine consultant dermatologists. ”
    Source data from
    2012-01-01
    Accessed
    2026-11-16
    Verification
    Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
    Calculation
    The overtreatment frame for the action side: even in expert hands, roughly six benign moles are excised for every melanoma found (far higher in primary care, where ~20 benign lesions are removed per melanoma). Most people who have a suspicious mole removed will learn it was harmless — the excision was, in hindsight, unnecessary. This is the cost the action side trades for certainty. Not a regret rate; context for why action regret, though low, is non-zero.

Sources: inaction

Claim ledger

Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.

2/2 sources independently verified verbatim against the cited source

  1. [1] BMC Cancer (O'Shea et al. 2017) — Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study Verified
    Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study
    Statistic
    27% of melanoma patients (n=40 of 159) delayed presentation more than 3 months; 44% (n=66) had not realised the symptom was serious — the most common barrier
    Excerpt
    “"A delay of greater than 3 months was reported by 27% of patients ( n = 40).' … 'Forty-four per cent ( n = 66) had not realised that the symptom was serious, which was the most common barrier reported' … 'Of the 149 patients who reported symptoms, 76% ( n = 113) described a change in a pre-existing mole rather than a new mole or lesion." ”
    Source data from
    2017-01-04
    Accessed
    2026-06-21
    Verification
    Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
    Calculation
    The inaction-regret proxy: among people whose mole turned out to be melanoma, 27% had watched and waited more than three months before presenting, and 44% had not recognised the change as serious. Watching a changing mole that proves malignant is the regretted inaction. Note the population: this is melanoma patients, not the general public — the proxy applies to the suspicious/changing-mole decision, not to leaving an unchanging benign mole alone (which carries near-zero regret and is the correct choice).
  2. [2] BMC Family Practice (Walter et al. 2010) — Patient understanding of moles and skin cancer, and factors influencing presentation in primary care: a qualitative study Verified
    Patient understanding of moles and skin cancer, and factors influencing presentation in primary care: a qualitative study
    Statistic
    Qualitative study (n=40): changing moles often perceived as trivial; patients delayed to avoid 'wasting the doctor's time'; three of four people later diagnosed with melanoma did not seek help — the GP noticed the lesion opportunistically
    Excerpt
    “"Changing moles are often perceived as trivial and not signifying possible skin cancer. ... 'I left it a couple of weeks and I just thought well, you know, I've got to be sensible about this, rather than wasting doctor's time' ... Three of four people subsequently diagnosed with melanoma did not seek help; instead, their GP opportunistically noticed the lesion." ”
    Source data from
    2010-08-09
    Accessed
    2026-06-21
    Verification
    Excerpt independently re-fetched and confirmed word-for-word against the cited source during our grounding audit.
    Calculation
    Qualitative corroboration of why watchful waiting on a changing mole is regretted in hindsight: the change is dismissed as trivial, and most melanomas in this sample were caught by the doctor rather than the patient. Provides the mechanism behind the O'Shea delay figure; does not supply the rate.

Caveats

This entry is deliberately scoped to a CHANGING or SUSPICIOUS mole, not to moles in general. Leaving an ordinary, stable, benign mole alone is the correct choice for almost everyone and carries near-zero regret — removing every mole would be mass overtreatment. The two sides are drawn from non-comparable populations and are construct-mismatched: the action-side figure is a recurrence/cosmetic-dissatisfaction proxy from nevus-excision outcome studies (Guo & Wang 2026, n=4,201 lesions), while the inaction-side 27% is a delayed-presentation rate among people whose mole was melanoma (O'Shea 2017, n=159). The inaction harm is conditional and concentrated: most suspicious moles are benign (Sidhu 2012 — roughly six benign lesions excised per melanoma found, even by specialists), so for the majority, watching and waiting ends without harm; but for the minority whose mole is malignant, delay can be severe or fatal. No survey directly asks adults "do you regret removing that mole?" or "do you regret not getting that changing mole checked?", so both rates are proxies and no precise comparison is drawn. Populations are UK, Australian, and pooled-international rather than US. The action side also delivers diagnostic certainty (histology) that the satisfaction figures do not price in. How much regret either choice carries turns heavily on the base rate of malignancy in the specific mole, which only a clinician can assess.

Raw data: /api/decisions.json

Recently viewed on this device